Special Issue "Cancer Cell Imaging"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 July 2013
Dr. Brigitta G. Baumert
Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Centre (MUMC) and GROW Research Institute, The Netherlands
Interests: CNS tumors; sarcomas; pet imaging; new MRI imaging techniques introduced for radiation therapy; new international trials in primaruy and secondary brain tumors
Dr. Shaker A. Mousa
Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, New York 12144, USA
Phone: +1 518 694 7397
Fax: +1 518-694 7567
Interests: Drug discovery and drug development utilizing key enabling technologies including nanotechnology; biotechnology, stem cell, and novel pharmacotherapy; cell adhesion molecules and extracellular matrix; treatment and prevention of ischemic and coronary artery diseases; angiogenesis modulation; vascular and tissue remodeling; novel anti-platelet, anti-thrombotic and early detection and treatment of diseases with unmet medical need ranging from oncology, ophthalmology, cardiovascular, and vascular disorders
The role of Nanotechnology in Cancer Imaging uisng specific molecular targeted strategies for early detection, effective treatment and therapeutic mointoring Cancer cells have unique properties that can be exploited by nanoparticles. Guided by and/or in conjunction with molecular imaging technologies, nanoparticles can be targeted at cancer cells to detect, monitor disease, deliver drugs, such as chemotherapy and to treat through ablation. Nano-Targeting of specific cancer cell types could serve as an emerging molecular imaging technology for effective early detection (Imaging), targeted therapy, and therapeutic monitoring. Cancer imaging involves the use of molecular imaging probes to accurately diagnose, manage and treat many types of cancer, which can be enhanced with the use of various nanoparticles. Tumor Imaging using existing platforms (MRI, PET, SPECT, CT, and others) might be enhanced with the use of Nano-probes in determining the stage and the precise locations of cancer to aid in surgery and other cancer treatments. Additionally, certain types of cancer the earlier it is detected the better are the chances of treating it effectively.
Nanotechnology based molecular imaging have the potential in enhancing the standard care for many types of cancer. Nano-Targeting based on molecular imaging would provide an effective and safe means of target-specific drug delivery. Cancer imaging would facilitate the followings: Identify Tumor Properties and Growth, Effective Treatment, and Treatment Monitoring. Nano-based Molecular imaging and therapy could bring us closer to personalized cancer treatment to optimize response and minimize toxicity. Potential uses of Nano-based molecular imaging biomarkers might provide surrogate endpoints, prognostic, and predictive biomarkers.
Technologies under development to be covered as well include: Optical imaging: For imaging gene expression; cell trafficking; therapeutic monitoring; the detection of ovarian cancer, malignant skin lesions, lymphoma, and intestinal adenoma; drug delivery and photoablation. Optical imaging is primarily used as a research tool although some applications are entering initial clinical testing. Targeted Ultrasound: Providing differential diagnoses of cancer, including breast, ovarian, head and neck, prostate, liver and pancreatic as well as drug delivery High-field MR spectroscopy: As an adjunct to breast MRI, distinguishing malignant from benign tissue; helping to differentiate between recurrent brain tumors and changes due to radiation treatments; and guiding radiation treatment of recurrent brain tumors and prostate cancer Diffusion Tensor Imaging: For diagnosing cerebral ischemia and investigating brain disorders including tumors. It measures the anisotropy of microscopic water molecules surrounding the brain's white matter fibers. Fusion imaging: Provides the ability to view molecular information within an anatomic context. This capability can be applied to PET, US, SPECT, MRI, MR spectroscopy and a growing range of optical technologies. Perfusion imaging: to differentiate betwen for example between tumor progression and pseudoprogression. This is of specific intererst in brain tumours. Imaging for radiation planning; imaging not only in the form of a planning CT but also PET-CT with different tumor related tracers and MRI is used for radiotherapy tumor definition but also for definition as a prognostic marker.
Dr. Brigitta G. Baumert
Dr. Shaker A. Mousa
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
Cancers 2013, 5(2), 550-568; doi:10.3390/cancers5020550
Received: 22 March 2013; in revised form: 13 April 2013 / Accepted: 10 May 2013 / Published: 15 May 2013| Download PDF Full-text (383 KB) | Download XML Full-text
Last update: 29 January 2013